There is no single “best” diabetes medicine for everyone. The right choice depends on your blood sugar levels, weight, heart and kidney health, and what you can afford. That said, metformin has been the default first-line treatment for Type 2 diabetes for decades, and it remains the starting point for most people who need blood sugar control without other complicating factors. Newer drug classes, particularly GLP-1 receptor agonists and SGLT2 inhibitors, have changed the landscape by offering benefits that go well beyond lowering blood sugar.
Why Metformin Is Still the Starting Point
Metformin works by reducing the amount of sugar your liver releases into your bloodstream and by helping your cells respond better to insulin. It typically lowers A1C by about 1 to 1.5 percentage points, which is enough for many people with newly diagnosed Type 2 diabetes. It rarely causes low blood sugar on its own, it’s weight-neutral or causes modest weight loss, and it costs as little as $4 a month, even without insurance.
The most common complaints are digestive: nausea, bloating, and diarrhea, especially in the first few weeks. An extended-release version reduces these symptoms for most people. Metformin isn’t safe for everyone. People with severe kidney disease, active liver disease, or conditions that reduce oxygen in the blood should avoid it because of a rare but serious complication called lactic acidosis, where acid builds up in the bloodstream faster than the body can clear it.
GLP-1 Receptor Agonists: The Strongest Blood Sugar and Weight Results
GLP-1 receptor agonists (brand names include Ozempic, Trulicity, and Victoza) mimic a gut hormone that triggers insulin release after meals, slows digestion, and reduces appetite. They lower A1C by roughly 0.5 to 1.5 percentage points, with the higher end seen at stronger doses. But their standout feature is weight loss. Many people on these medications lose 5 to 10% or more of their body weight, which independently improves blood sugar, blood pressure, and cholesterol.
A newer dual-action medication, tirzepatide (Mounjaro), targets two gut hormones instead of one. In head-to-head comparisons with semaglutide (Ozempic’s active ingredient), tirzepatide at its mid and high doses produced roughly 4 to 5.4 percentage points more weight loss and an additional 0.4% A1C reduction. It also caused slightly fewer gastrointestinal side effects. For people who need substantial blood sugar lowering and weight reduction, these medications are currently the most effective non-insulin options available.
The major downside is cost. Without insurance, a month’s supply of Ozempic runs $1,000 to $1,400. Even with insurance, copays can range from $25 to $200 per month. Compare that to metformin’s $4 to $15 out-of-pocket cost, and the gap is enormous. Nausea is the most common side effect, and it can be significant in the first weeks, though it usually fades as your body adjusts.
SGLT2 Inhibitors: Best for Heart and Kidney Protection
SGLT2 inhibitors (empagliflozin and dapagliflozin are the most studied) work by causing your kidneys to flush excess sugar out through urine. The A1C reduction is moderate, but these drugs have proven benefits that no other diabetes medication class can match when it comes to protecting the heart and kidneys.
In large clinical trials, dapagliflozin reduced cardiovascular death in people with heart failure, and empagliflozin cut the risk of kidney function decline by 50% compared to placebo. These benefits held up regardless of whether patients had existing kidney disease at the start. For someone with Type 2 diabetes who also has heart failure or declining kidney function, an SGLT2 inhibitor is often prioritized over pure blood sugar considerations.
Because these medications work through the kidneys, they increase urinary frequency and can raise the risk of urinary tract infections and genital yeast infections. They also carry a small risk of a rare condition called diabetic ketoacidosis, where the blood becomes dangerously acidic. They cause modest weight loss, typically a few pounds, and they lower blood pressure slightly.
DPP-4 Inhibitors: A Milder Option
DPP-4 inhibitors (sitagliptin, linagliptin, and others) work on a similar pathway as GLP-1 medications but with a much weaker effect. They lower A1C by about 0.5 to 1.0 percentage points, don’t cause weight loss, and don’t have the cardiovascular or kidney benefits of SGLT2 inhibitors. Their main advantage is that they’re well tolerated, with few side effects and very low risk of causing low blood sugar. They’re sometimes used in older adults or people who can’t tolerate other options, but they’re rarely the first add-on choice anymore given the stronger alternatives available.
When Combination Therapy Makes Sense
Many people need more than one medication. Current guidelines recommend starting combination therapy right away if your A1C is 1.5 to 2.0 percentage points above your target. For most adults, the target A1C is around 7%, so if you’re diagnosed at 8.5% or higher, your doctor may start two medications from the beginning rather than waiting for metformin alone to work.
The most common pairings add a GLP-1 receptor agonist or an SGLT2 inhibitor to metformin. Because these drug classes work through completely different mechanisms, they complement each other well. Someone with heart failure might get metformin plus an SGLT2 inhibitor. Someone who needs significant weight loss might get metformin plus a GLP-1 agonist. Someone with both concerns could potentially use all three.
If blood sugar is very high at diagnosis, with an A1C above 10% or blood sugar readings above 300 mg/dL, insulin is often started immediately regardless of what other medications are in the picture. This isn’t a failure. It’s the fastest way to bring dangerously high blood sugar under control, and some people can eventually transition off insulin as other medications and lifestyle changes take effect.
How Age and Health Shape the Choice
Older adults face a specific set of tradeoffs. Hypoglycemia (low blood sugar) is more dangerous as you age because the warning signs shift. Instead of the obvious tremors and sweating that younger people feel, older adults are more likely to experience dizziness, confusion, or weakness, which can lead to falls, hospitalizations, and even long-term cognitive decline. Repeated severe episodes of low blood sugar have been linked to higher dementia risk.
This makes medications that don’t cause low blood sugar, like metformin, GLP-1 agonists, SGLT2 inhibitors, and DPP-4 inhibitors, preferable in older adults. Sulfonylureas (glipizide, glyburide) and insulin both carry meaningful hypoglycemia risk and should be used cautiously, especially in frail or elderly patients. A1C targets are also relaxed for older adults with limited life expectancy or multiple health conditions, which sometimes means less aggressive medication regimens overall.
Choosing Based on Your Priorities
The “best” diabetes medicine depends on what matters most in your situation:
- Affordability and simplicity: Metformin is inexpensive, available as a generic pill, and effective for mild to moderate blood sugar elevation.
- Maximum blood sugar and weight reduction: GLP-1 receptor agonists or tirzepatide deliver the strongest results but come at a high price and require injections (weekly for most).
- Heart or kidney protection: SGLT2 inhibitors have the best evidence for reducing heart failure events and slowing kidney disease progression.
- Minimal side effects: DPP-4 inhibitors are the most tolerable but offer the least benefit beyond blood sugar lowering.
For many people, the answer ends up being more than one medication working together. Type 2 diabetes is progressive, meaning the body’s ability to manage blood sugar tends to decline over time. A treatment plan that works well at diagnosis may need adjustments in a year or five years. The goal isn’t to find one perfect pill but to match your medications to your body’s current needs, your other health conditions, and what you can realistically afford and stick with.